Amylyx Pharmaceuticals (NASDAQ:AMLX) CEO Justin Klee Sells 1,995 Shares

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) CEO Justin Klee sold 1,995 shares of the business’s stock in a transaction dated Friday, January 16th. The stock was sold at an average price of $13.89, for a total transaction of $27,710.55. Following the completion of the sale, the chief executive officer owned 3,379,398 shares in the company, valued at $46,939,838.22. This represents a 0.06% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Amylyx Pharmaceuticals Trading Up 15.7%

Shares of NASDAQ AMLX opened at $16.55 on Wednesday. The company’s 50-day moving average price is $13.17 and its 200 day moving average price is $11.75. Amylyx Pharmaceuticals, Inc. has a 52 week low of $2.60 and a 52 week high of $16.96. The stock has a market cap of $1.82 billion, a price-to-earnings ratio of -9.19 and a beta of -0.31.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last announced its quarterly earnings results on Thursday, November 6th. The company reported ($0.37) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.43) by $0.06. As a group, research analysts expect that Amylyx Pharmaceuticals, Inc. will post -2.2 earnings per share for the current year.

Hedge Funds Weigh In On Amylyx Pharmaceuticals

Large investors have recently added to or reduced their stakes in the business. Aster Capital Management DIFC Ltd purchased a new position in shares of Amylyx Pharmaceuticals in the third quarter valued at $48,000. California State Teachers Retirement System purchased a new stake in Amylyx Pharmaceuticals during the 2nd quarter worth $28,000. BNP Paribas Financial Markets lifted its holdings in Amylyx Pharmaceuticals by 433.2% in the 2nd quarter. BNP Paribas Financial Markets now owns 7,267 shares of the company’s stock worth $47,000 after buying an additional 5,904 shares in the last quarter. Ameritas Investment Partners Inc. purchased a new position in Amylyx Pharmaceuticals in the 2nd quarter valued at about $45,000. Finally, Legal & General Group Plc acquired a new stake in shares of Amylyx Pharmaceuticals during the second quarter valued at about $47,000. 95.84% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on AMLX shares. Lifesci Capital raised Amylyx Pharmaceuticals to a “strong-buy” rating in a research report on Monday, October 27th. Citigroup upped their price objective on Amylyx Pharmaceuticals from $12.00 to $20.00 and gave the company a “buy” rating in a research report on Friday, October 17th. Robert W. Baird lifted their price objective on Amylyx Pharmaceuticals from $10.00 to $19.00 and gave the stock an “outperform” rating in a research report on Thursday, October 16th. Weiss Ratings reissued a “sell (d-)” rating on shares of Amylyx Pharmaceuticals in a research note on Monday, December 29th. Finally, HC Wainwright raised their price target on shares of Amylyx Pharmaceuticals from $16.00 to $20.00 and gave the stock a “buy” rating in a research note on Friday, November 7th. Two analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $17.25.

About Amylyx Pharmaceuticals

Amylyx Pharmaceuticals, Inc is a biopharmaceutical company dedicated to developing treatments for rare and debilitating neurological diseases. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company focuses on leveraging novel approaches to target cellular pathways implicated in neurodegeneration. Amylyx’s research platform centers on small-molecule therapies designed to protect neurons and support cellular health in patients with conditions that currently have limited or no disease-modifying treatment options.

The company’s lead product, AMX0035, is marketed under the trade name Relyvrio following U.S.